Predicted Failure Still Hurts

Just because you expect something to turn out poorly doesn't mean you're happy to be proven correct. Alzheimer's disease treatment bapineuzumab is officially dead after failing its second phase 3 trial. What does this mean for the trio of stocks involved with it -- and the one Big Pharma player with a lot riding on its version of the drug? Watch and find out.

Many investors are attracted to health care for the substantial short-term gains that positive trial results provide. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

The article Predicted Failure Still Hurts originally appeared on Fool.com.

David Williamson owns shares of Johnson & Johnson and Pfizer, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Pfizer and Johnson & Johnson. Motley Fool newsletter services have recommended creating a diagonal call position in Johnson & Johnson. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.